OIPE JC135
APR 10 2002
PATENT & TRADEMARK OFFICE

✓ 21



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

| Atty Docket No. | Serial No. |
|---|---|
| P1256R3 | 09/209,023 |
| Applicant: Paton et al. | |
| Filing Date: 10 Dec 1998 | Group: 1642 |

**LIST OF DISCLOSURES CITED BY APPLICANT**

(Use several sheets if necessary)

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

| | | |
|---|---|---|
| AU | 167 | "Are adjuvant Herceptin trials using the wrong drugs?" Scrip 2493:21 (Nov 26, 1999) |
| AU | 168 | Burris et al., "Phase II trial of docetaxel and Herceptin(R) as first- or second-line chemotherapy for women with metastatic breast cancer whose tumours overexpress HER2" European Journal of Cancer (Abstract no. 1293) 35(4):S322 (Sep 1999) |

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

Examiner: Anne L Kelleran

Date Considered: 2/23/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.